Results 161 to 170 of about 21,696 (215)

Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial.

JAMA Dermatol
Mangold AR, Lockshin B, Lai Z, Rong R, Nawaz H, Ehst BD.   +5 more
europepmc   +1 more source

The bidirectional relationship between <i>JAK2V617F</i> allele burden and inflammation in polycythaemia vera: Insights from interferon and ruxolitinib therapy. [PDF]

Hemasphere
Barbui T, Guglielmelli P, Vannucchi AM.
europepmc   +1 more source

HLHRUXO: a prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis. [PDF]

Blood Adv
Meyer LK, Ryan K, Panetta JC, Crews KR, Albeituni S, Degar BA, Hermiston ML, Talano JM, Torno LL, Zambidis ET, Trone DJ, Sabin ND, Maron G, Flerlage T, Thomas PG, Cheng C, Campbell PK, Nichols KE, Hines MR.   +18 more
europepmc   +1 more source

Abstracts of 14th International Symposium on Hodgkin Lymphoma

HemaSphere, Volume 10, Issue S2, October 2026.
wiley   +1 more source

Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review. [PDF]

Medicine (Baltimore)
Jin LY, Yu P, Huo F, Cui YH, Wu BL, Li T.   +5 more
europepmc   +1 more source

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib. [PDF]

Blood Adv
Palandri F, Dedola A, Caocci G, Rossi E, Elli EM, Sartor C, Latagliata R, Pugliese N, Morsia E, Binotto G, Mendicino F, Tieghi A, Benevolo G, Martino B, D'Addio A, Tiribelli M, Cilloni D, Crugnola M, Cavalca F, Scalzulli E, Lanza F, Pane F, Palumbo GA, Heidel FH, De Stefano V, Breccia M, Branzanti F.   +26 more
europepmc   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways. [PDF]

Br J Haematol
Kashyap T, Ellero AA, Walker CJ, Maloof ME, Lu M, Xia L, Hoffman R, Taverna P.   +7 more
europepmc   +1 more source

Selinexor for myelofibrosis or a drug in search of a disease? [PDF]

Blood Cancer J
Gangat N, Tefferi A.
europepmc   +1 more source

Ruxolitinib prevents irreversible autoimmune endocrinopathies in APECED. [PDF]

Nat Commun
Pechacek J, Webb T, Dos Santos Dias L, Wu R, Moorman H, Barber P, Rosen LB, Burbelo PD, Colton B, Guzman H, Sacta M, McCormack SE, Bennett A, Loomes K, Romberg N, McGrath N, Holland SM, Heller T, Winer KK, Pittaluga S, Lionakis MS.   +20 more
europepmc   +1 more source

Longitudinal prospective analysis of organ stiffness and cardiac function in patients with myelofibrosis treated with ruxolitinib type of study: Prospective single-center cohort study. [PDF]

Ther Adv Hematol
Lekovic D, Arsenovic I, Cvetkovic M, Matic D, Stojkovic Lalosevic M, Cvejic Pasic T, Starcevic J, Bogdanovic A.   +7 more
europepmc   +1 more source